Core Insights - OXB has been awarded the 'Most Innovative CDMO (Cell & Gene Therapy)' at the CDMO Leadership Awards in New York City, highlighting its leadership and innovation in the CDMO industry [1][2] - This recognition follows OXB's previous accolades, including a win in the 'Cell & Gene Therapy – Global' category in 2025 and being named a Champion in the 'Cell & Gene Therapy' category at the CDMO Leadership Awards Europe [2] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver life-changing therapies worldwide [4][5] - The company has 30 years of experience in viral vectors, which are essential for most cell and gene therapies, and collaborates with leading pharmaceutical and biotechnology companies [5] - OXB's capabilities span from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise [5] Technological Capabilities - OXB offers a wide range of technologies for viral vector manufacturing, including the 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6] - The company employs advanced processes such as suspension and perfusion using process enhancers, along with stable producer and packaging cell lines [6] Facilities and Presence - OXB is headquartered in Oxford, UK, with development and manufacturing facilities located in Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford MA and Durham NC, US [7]

Core Insights - OXB achieved a significant revenue growth of 33% on a constant currency basis, reaching £170.9 million, and reported revenues increased by 31% to £168.7 million for the year ended 31 December 2025, demonstrating strong commercial momentum and operational execution [2][7][39] - The company reported an Operating EBITDA profit of £2.3 million, a substantial improvement from a loss of £15.3 million in 2024, driven by revenue growth and a focus on operating costs [7][39][79] - OXB's strategic execution included the acquisition of an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing its capabilities in the growing cell and gene therapy market [3][25][59] Financial Performance - Revenue from manufacturing services increased by 18.6% to £81.1 million, while development services grew by 27.1% to £60.1 million, and procurement services surged by 284.5% to £22.3 million [5][71] - Gross profit rose by 23.8% to £66.0 million, with a gross margin of 39% [5][76] - The revenue backlog increased by approximately 36% to around £204 million, indicating strong future revenue visibility [7][41] Strategic Expansion - OXB's acquisition of the Durham facility for $4.5 million (£3.3 million) added significant manufacturing capabilities and supports late-stage client programs and commercial launches [25][39][59] - The company entered into a new multi-year Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors, further solidifying its market position [7][45] - OXB's global CDMO network expansion is supported by a new four-year term loan facility of up to $125 million with Oaktree Capital Management and an equity raise of approximately £60 million [24][66] Market Position and Outlook - The global cell and gene therapy pipeline grew to 2,251 candidates, reflecting a robust market environment that OXB is well-positioned to capitalize on [26][39] - OXB anticipates FY 2026 revenues between £220-240 million, with an expected Operating EBITDA margin of around 10% [14][36] - The company aims for medium-term revenue growth of 25-30% in FY 2027-2028, with EBITDA margins projected to rise to at least 20% in FY 2027 [7][14] Innovation and Technology - OXB continues to focus on innovation, enhancing its viral vector manufacturing capabilities and integrating advanced technologies such as mass spectrometry and AI for process optimization [28][49][51] - The establishment of the Innovation and Technology Excellence Board aims to drive strategic investments in scalable technologies, ensuring OXB remains at the forefront of scientific advancement [29][39] Governance and ESG Initiatives - OXB strengthened its governance framework with new board appointments and incorporated ESG-linked key performance indicators into annual bonus arrangements, reflecting its commitment to sustainability [30][34] - The company achieved a reduction in operational emissions by over 6% and advanced its social responsibility agenda through enhanced employee engagement initiatives [32][33]

Core Insights - OXB has entered into a licensing and option agreement with VVMF, Australia's first commercial manufacturing facility for viral vectors, to enhance its global reach in cell and gene therapy [1][2][4] Group 1: Agreement Details - The agreement grants VVMF a worldwide, non-exclusive license to OXB's inAAVate™ platform and an option for the LentiVector™ platform, with OXB receiving a low single-digit million license fee and potential future payments [2][3] - This five-year license aims to accelerate VVMF's operational and commercial readiness, focusing on the growing demand in the APAC region [3][4] Group 2: Strategic Implications - The collaboration reinforces OXB's position as a trusted provider of viral vector development and manufacturing services, highlighting the scalability and reliability of its platforms [4][5] - VVMF aims to leverage OXB's expertise to establish a leadership position in the APAC region, enhancing its operational capabilities and aligning with industry standards [6][5] Group 3: Company Background - OXB is a pioneer in cell and gene therapy with 30 years of experience in viral vectors, collaborating with leading pharmaceutical and biotechnology companies [9][12] - The company offers a range of technologies for viral vector manufacturing, including advanced systems for lentiviral and AAV production [10][9]

Core Insights - OXB expects to report revenues for FY 2025 at the upper end of guidance, with a significant growth trajectory and a pivot towards EBITDA profitability [2][3][8] - The company reiterates its financial guidance for 2026, maintaining expectations for continued revenue growth and improved EBITDA margins [9][20] Financial Performance - For FY 2025, OXB anticipates revenues between £166-169 million, reflecting a nearly 30% increase from FY 2024 revenues of £128.8 million and almost 90% growth since FY 2023 [3][8] - The expected Operating EBITDA profitability for FY 2025 is mid-to-high single-digit million pounds, including a non-recurring gain from the acquisition of a manufacturing facility [4][19] - The contracted value of client orders reached £224 million for FY 2025, a 20% increase from £186 million in FY 2024, indicating strong demand for OXB's services [6][8] Future Outlook - FY 2026 revenues are projected to be between £220-240 million, with anticipated year-on-year growth of 25-30% in 2027 and 2028, outpacing the broader market [9][20] - Operating EBITDA margin is expected to exceed 10% in FY 2026 and reach at least 20% for FY 2027, with long-term potential approaching 30% as capacity expands [9][20][21] Operational Efficiency - The company has demonstrated improved operational efficiency across its global network, contributing to sustained revenue growth and profitability [3][4] - A strong balance sheet is maintained, with a gross cash position of £96.9 million and a net cash position of £55.4 million, bolstered by a £60 million equity raise and a new loan facility [5][6]

Core Insights - OXB has been recognized as a Champion in the 'Cell & Gene Therapy' category at the 2025 CDMO Leadership Awards Europe, reflecting its high performance based on feedback from biopharmaceutical professionals [1][2] - This recognition highlights OXB's excellence in quality, innovation, and service, coinciding with strong commercial momentum driven by increased demand for its CDMO services [2][3] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver life-changing therapies [4][5] - The company has 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies to provide expertise in various viral vector types [5][6] - OXB's capabilities range from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise [5][6] Technological Capabilities - OXB offers a wide range of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6] - The company utilizes advanced processes such as suspension and perfusion processes with process enhancers and stable producer and packaging cell lines [6] Industry Recognition - The CDMO Leadership Awards recognize organizations that excel in quality, capabilities, expertise, reliability, compatibility, and service, based on direct feedback from industry professionals [8]

Core Insights - OXB, a leading CDMO in cell and gene therapy, will participate in several upcoming investor conferences and events, showcasing its commitment to engaging with investors [2][3]. Conferences and Events - OXB will attend the Stifel Healthcare Conference in New York and the Jefferies Global Healthcare Conference in London [3]. - A virtual event, the Jefferies C-Suite "Back to School" Fireside Chat, is scheduled for November 4, 2025, with live webcasts available on OXB's website [3][4]. - Additional financial events can be found on the company's investor calendar [4]. Company Overview - OXB has 30 years of experience in viral vectors, essential for most cell and gene therapies, and collaborates with innovative pharmaceutical and biotechnology companies [7]. - The company offers a range of technologies for viral vector manufacturing, including the TetraVecta™ system for lentiviral vector production and advanced AAV production methods [9]. - OXB is a FTSE250 and FTSE4Good constituent, with facilities in the UK, France, and the US, emphasizing its global presence and capabilities [9].

Core Insights - OXB has acquired a state-of-the-art viral vector manufacturing facility in North Carolina from RTP Operating, LLC, enhancing its capabilities in the cell and gene therapy sector [1][8] - The acquisition aligns with OXB's strategic initiatives to expand its US commercial capabilities and meet growing client demand [4][7] Group 1: Acquisition Details - The facility is FDA approved and adds commercial-scale GMP capacity, enabling OXB to support late-stage programs and commercial launches for clients worldwide, particularly in the adeno-associated virus (AAV) field [2][9] - OXB paid $4.5 million (£3.4 million) for the assets, funded by existing cash, with integration planning expected to be operational by Q1 2026 [5][6] Group 2: Operational Enhancements - The North Carolina site includes two operational GMP drug substance suites, a dedicated fill-finish suite, and on-site QC labs, complementing OXB's existing global network [3][11] - The company plans to invest in the new facility, including hiring additional operational staff to enhance US fill-finish capacity and expedite client onboarding [6][8] Group 3: Financial Outlook - The acquisition is expected to support OXB's long-term top-line growth and maintain existing financial guidance, with an anticipated single-digit gain in 2025 [5][7] - OXB aims to achieve EBITDA profitability from FY 2025 and strengthen its competitive position in the global viral vector market [7][9]

Core Viewpoint - OXB has shown strong commercial momentum and operational progress in 2025, continuing to provide viral vector manufacturing services to a diverse client base, and remains on track to meet its financial outlook for the year ended December 31, 2024 [2][3]. Group 1: Company Performance - OXB has delivered strong operational performance in the first half of 2025, reflecting disciplined execution across global sites and sustained commercial momentum [3]. - The company reiterates its financial guidance and remains focused on supporting clients at all development stages, expressing confidence in its near and medium-term targets [3]. Group 2: Company Background - OXB is a pioneer in cell and gene therapy with 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies [5]. - The company provides expertise in various viral vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus, supporting capabilities from early-stage development to commercialization [5]. Group 3: Technological Capabilities - OXB offers unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6]. - The company utilizes advanced processes such as suspension and perfusion with process enhancers, along with stable producer and packaging cell lines [6]. Group 4: Corporate Information - OXB is headquartered in Oxford, UK, with development and manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford, MA, US [7].

Core Insights - OXB has launched the Innovation and Technology Excellence Board (ITEB) to enhance its capabilities in cell and gene therapy and maintain its leadership position in the market [1][2][3] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver transformative therapies to patients [15][16] - The company has 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies [16] Strategic Initiatives - The ITEB will provide strategic insights to identify opportunities for scientific enhancement and innovation, ensuring OXB remains at the forefront of technology development [2][3] - The board aims to improve treatment development, manufacturing, and delivery processes, focusing on practical advances for clients and better patient outcomes [3] Leadership and Expertise - The ITEB is chaired by Prof. Dame Kay Davies, a respected figure in human genetics, with founding members including leading experts in molecular biology, gene therapy, and biopharmaceuticals [3][4][5][6][7] - Dr. Frank Mathias, CEO of OXB, emphasizes the importance of the ITEB in adapting to scientific and technological changes to better serve clients [3][10] Technological Capabilities - OXB offers unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system and advanced AAV production methods [17] - The company supports its capabilities with robust quality-assurance systems and regulatory expertise, facilitating a range of services from early-stage development to commercialization [16]